|
|
epigallocatechin-3-gallate |
|
Vaxjo ID |
336 |
|
Vaccine Adjuvant Name |
epigallocatechin-3-gallate |
|
Adjuvant VO ID |
VO_0005599
|
|
Description |
novel adjuvant derived from catechins from green tea that induces mixed Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
Korea |
|
Host Species for Testing |
Mouse |
|
Components |
Green tea catechin, epigallocatechin-3-gallate (EGCG), |
|
Structure |
aromatic polyphenol, contains 3-galloyl group, compound comprising a large number of hydroxyl groups |
|
Molecular Weight |
458 Da |
|
Appearance |
Light green powder (as typical for purified EGCG ?98%) |
|
Storage |
stored in powder form reconstituted in distilled water for use |
|
Preparation |
adding distilled water to purified (98%) poweder |
|
Dosage |
70–700 µg per dose in mice Given IM or IP, three times, every 2 weeks |
|
Function |
Type: plant-derived vaccine adjuvant. Induces Th1/Th2 mixed immune profile. induced high levels of neutralizing antibodies, comparable to that induced by alum, providing complete protection against the lethal challenge |
| References |
Cheong et al., 2021: Cheong Y, Kim M, Ahn J, Oh H, Lim J, Chae W, Yang SW, Kim MS, Yu JE, Byun S, Jang YH, Seong BL. Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant. Frontiers in immunology. 2021; 12; 769088. [PubMed: 34868027].
Lecumberri et al., 2013: Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clinical nutrition (Edinburgh, Scotland). 2013; 32(6); 894-903. [PubMed: 23582951].
|
|
